Note 8 - Fair Value Measurements (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Notes Tables |
|
| Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] |
| | | Fair Value Measurements at October 1, 2024 (Issuance) | |
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | | | Other Observable Inputs (Level 2) | | | Significant Unobservable Inputs (Level 3) | | | Total | |
| Derivative liabilities - warrants | | $ | — | | | $ | — | | | $ | 19,494,000 | | | $ | 19,494,000 | |
| Total | | $ | — | | | $ | — | | | $ | 19,494,000 | | | $ | 19,494,000 | |
| | | Fair Value Measurements at December 31, 2024 | |
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | | | Other Observable Inputs (Level 2) | | | Significant Unobservable Inputs (Level 3) | | | Total | |
| Derivative liabilities - warrants | | $ | — | | | $ | — | | | $ | 16,400,000 | | | $ | 16,400,000 | |
| Total | | $ | — | | | $ | — | | | $ | 16,400,000 | | | $ | 16,400,000 | |
| | | Fair Value Measurements at December 31, 2025 | |
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | | | Other Observable Inputs (Level 2) | | | Significant Unobservable Inputs (Level 3) | | | Total | |
| Derivative liabilities - warrants | | $ | — | | | $ | — | | | $ | 50,000 | | | $ | 50,000 | |
| Total | | $ | — | | | $ | — | | | $ | 50,000 | | | $ | 50,000 | |
|
| Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] |
| | | December 31, 2025 | | | December 31, 2024 | | | October 1, 2024 (Issuance) | |
| Exercise price | | $ | — | | | $ | 1.9445 | | | $12.00 - $25.00 | |
| Stock price | | $ | 0.8138 | | | $ | 3.4700 | | | $ | 7.9100 | |
| Expected term (year) | | | 3.75 | | | | 4.75 | | | | 5.00 | |
| Volatility | | | 140.18 | % | | | 133.00 | % | | | 108.00 | % |
| Risk-free rate | | | 3.64 | % | | | 4.28 | % | | | 3.45 | % |
| Dividend yield | | | — | % | | | — | % | | | — | % |
| Probability of capital raise below exercise price | | | 100 | % | | | 100 | % | | | 100 | % |
|
| Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block] |
| | | Amount | |
| Gross proceeds | | $ | 6,466,500 | |
| Less: placement agent and legal fees | | | (778,261 | ) |
| Net proceeds | | | 5,688,239 | |
| Less: Series F issued for Alpha consent | | | (1,500,000 | ) |
| Less: Fair value of warrant liabilities at Issuance | | | (19,494,000 | ) |
| Loss on equity financing | | $ | (15,305,761 | ) |
|
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] |
| December 31, 2024 | | | Amount | |
| Balance, beginning of the year | | $ | — | |
| Warrant liabilities at issuance | | | 19,494,000 | |
| Change in fair value of warrant liabilities | | | (3,094,000 | ) |
| Balance, end of the year | | $ | 16,400,000 | |
| | | | | |
| December 31, 2025 | | | Amount | |
| Balance, beginning of the year | | $ | 16,400,000 | |
| Amended Series B warrants reclassified to stockholders' equity (deficit) | | | (7,766,000 | ) |
| Change in fair value of warrant liabilities | | | (8,584,000 | ) |
| Balance, end of the year | | $ | 50,000 | |
|